Skip to main content
Gates Foundation Author Manuscripts logoLink to Gates Foundation Author Manuscripts
. Author manuscript; available in PMC: 2018 Oct 18.
Published in final edited form as: N Engl J Med. 2018 Oct 17;379(18):1745–1753. doi: 10.1056/NEJMoa1804498

Genomic analysis of Lassa virus from the 2018 surge in Nigeria

Katherine J Siddle 1,*, Philomena Eromon 2,*, Kayla G Barnes 3,*, Judith U Oguzie 4,*, Samar Mehta 5,*, Ikponmwonsa Odia 6,*, Rickey Shah 7, Patrick Brehio 8, Sarah M Winnicki 9, Christopher Iruolagbe 10, John Aiyepada 11, Eghosa Uyigue 12, Patience Akhilomen 13, Grace Okonofua 14, Bridget Chak 15, Dylan Kotliar 16, Blessing Osiemi 17, Ekene Muoebonam 18, Michael Airende 19, Rachael Ukpetina 20, Iguosadolo Nosamiefan 21, Paul Oluniyi 22, Ephraim Ogbaini-Emovon 23, Mahan Nekouin 24, Onikepe A Folarin 25, Stephen F Schaffner 26, Robert F Garry 27, Kristian G Andersen 28, Daniel J Park 29, Nathan L Yozwiak 30, Bronwyn L MacInnis 31, George Akpede 32, Sylvanus Okogbenin 33, Peter Okokhere 34, Pardis C Sabeti 35,**, Christian T Happi 36,**,
PMCID: PMC6181183  PMID: 30332564

Abstract

In early 2018 Nigeria experienced an unprecedented increase in Lassa fever cases with widespread geographic distribution. We report 77 Lassa virus genomes generated from patient samples, 14 from 2018, to investigate whether recent changes in the virus genome contributed to this surge. Our data argue that the surge is not attributable to a single Lassa virus variant, nor has it been sustained by human-to-human transmission. We observe extensive viral diversity structured by geography, with major rivers appearing to act as barriers to migration of the rodent reservoir. Together our results support that the 2018 Lassa fever surge was driven by crossspecies transmission from local rodent populations of multiple viral variants from different lineages.

INTRODUCTION

Lassa fever is a viral hemorrhagic disease endemic to parts of Western Africa that causes over 300,000 cases and 3,000 fatalities per year1. It has been recognized by the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI) as a significant threat to global health and in need of urgent R&D attention2-4. Despite the burden of Lassa virus, there is currently no approved vaccine, and the only available pharmacologic therapy is early intravenous administration of the antiviral ribavirin5-7. In early 2018 there was a marked increase in Lassa fever cases in Nigeria: by early March, Nigeria had more confirmed cases (394) than in any previous year. Confirmed cases were observed in 19 Nigerian states, with an estimated case fatality rate of approximately 25%8. The factors underlying this increase were not known, raising concern among public health officials that something had fundamentally changed about this endemic disease.

In a presumed Lassa fever outbreak, genomic analysis of contemporaneous Lassa virus in samples from infected patients can complement conventional epidemiological data by determining whether changes to intrinsic properties of the virus explain the increase in cases. In particular, viral genomic analysis can rapidly assess whether a novel variant or specific viral lineage, or a change in viral transmission route is associated with the case surge. Most human Lassa virus infections result from contact with infected Mastomys natalensis (the major natural reservoir9) or their excreta, but human-to-human transmission has been documented in hospital settings and is a focus of public health monitoring10,11. Previous retrospective investigation of the genomic epidemiology of Lassa virus in Nigeria between 2008 and 2014 showed extensive genetic diversity across the region and provided support for predominantly reservoir-to-human transmission12. Subsequent studies have extended the known genetic diversity of Lassa virus, of which there are at least four firmly established lineages13, as well as its geographic range in Western Africa14,15. Against this backdrop, genomic analysis of Lassa virus during the 2018 can quickly establish changes in the viral genome associated with period of increased Lassa fever cases.

Here we report near real-time genome analysis of Lassa virus from patients from January to March 2018, undertaken at the African Center of Excellence for Genomics of Infectious Disease (ACEGID), at Redeemer’s University in Nigeria. These data provide important genomic context to the recent Lassa fever surge and further resolve the geographic structure of the endemic Lassa virus population across Nigeria.

METHODS

Patient sample collection

We obtained patient samples through a study evaluated and approved by Institutional Review Boards (IRBs) at Irrua Specialist Teaching Hospital (ISTH, Irrua, Nigeria), Redeemer’s University (Ede, Osun State, Nigeria), and Harvard University (Cambridge, Massachusetts). Study staff obtained informed consent from participants enrolled in the research study at ISTH. In addition, some samples were included under a waiver of consent to facilitate rapid public health response as the research involved minimal risk to the subjects. Samples from suspected Lassa fever cases were tested for Lassa virus by RT-qPCR (reverse transcriptase - quantitative polymerase chain reaction) at the clinical diagnostics laboratory at ISTH. We de-identified samples and obtained demographic and clinical data in line with ethical approvals. We prepared a subset of samples with positive Lassa virus RT-qPCR diagnosis, spanning the time frame of the surge, for sequencing.

Viral sequencing

We extracted RNA from patient plasma using the QiAmp viral RNA mini kit (Qiagen) or Pathogen RNA/DNA kit (MagMax) according to the manufacturer’s instructions. We removed contaminating DNA by DNase treatment, synthesized cDNA, and prepared sequencing libraries using the Nextera XT kit (Illumina) as previously described16. We constructed sequencing libraries directly from clinical samples without culture or other intervention. We extracted, prepared, and sequenced samples from 2018 at ACEGID, Redeemer’s University, Ede, Osun State, Nigeria, and those from prior to 2018 at ACEGID or the Broad Institute, Cambridge, MA, USA. We additionally performed replicate sequencing of samples from 2018 at the Broad Institute for intra-host variant detection. We sequenced all samples using Illumina MiSeq and HiSeq 2500 machines with 100 nucleotide paired-end reads.

Genomic data analysis

We analyzed sequencing data using our publicly available software viral-ngs v1.19.217,18 implemented on the DNAnexus cloud-based platform. Briefly, we demultiplexed individual libraries, removed reads mapping to the human genome and to other known technical contaminants (e.g. sequencing adapters), and filtered the remaining reads against previously published Lassa virus genomes. We performed de novo assembly using Trinity19 and scaffolded contigs against one of three Lassa virus reference genomes (KM821997-8, GU481072-3, KM821772-3), representing the major viral lineages (II, III and IV). We used Kraken v0.10.620 in viral-ngs to identify other viral taxa present in the samples. To do so, we first built a database that encompassed the known diversity of all viruses that infect humans (similar to that described elsewhere21, but without insect species). We searched for viral species detected in the samples with a read count at least 1.5x greater than that of any viral taxon identified in negative control samples and manually investigated any potential hits. We detected intra-host variants in samples from 2018 using V-Phaser 222 implemented in viral-ngs v1.19.2 using default parameters. To do so, we leveraged data from independently prepared replicate sequencing libraries for 13 of the 14 samples.

In order to construct the phylogenetic tree of Lassa virus, we performed a multiple sequence alignment of our new genomes with a set of 193 previously published Lassa virus genomes from Nigeria, Sierra Leone, Liberia, and Côte d’Ivoire12. We performed codon-based multiple sequence alignments of the NP and GPC sequences using MAFFT23. We estimated maximum likelihood phylogenies of concatenated alignments of NP and GPC using IQ-TREE v1.5.524,25 using a GTR substitution model and ultrafast bootstrapping. To create time-aware phylogenies for the Nigerian lineage II sequences, we then performed Bayesian phylogenetic analyses using the program BEAST v1.8.426, incorporating the collection date for each sequence. We included GPC and NP lineage II alignments as separate partitions. We used a model consisting of an SRD06 codon-aware nucleotide substitution model27, an uncorrelated relaxed clock with a lognormal distribution, and a Bayesian SkyGrid coalescent tree prior. All of the Bayesian analyses were run for 200 million MCMC steps, sampling parameters and trees every 5,000 generations. Maximum-clade credibility trees summarizing all MCMC samples were generated using TreeAnnotator v1.8.4 with a burn-in rate of 10%.

RESULTS

Lassa fever case burden at ISTH in 2018

The ISTH Lassa ward, with 16 beds, is the largest Lassa fever facility in Nigeria and a major diagnostic referral center, receiving suspected Lassa fever patient samples from across the country. From January 1 to March 13, 2018, ISTH tested over 1500 clinically suspected Lassa fever cases, of which 368 were RT-qPCR-positive for Lassa virus (Fig. 1A & 1B). This number, which represents the majority of confirmed cases in Nigeria during this period, is markedly higher than that observed in previous years (Fig. 1A). There is a wide distribution of ages (Fig. S1A) and geographic source of confirmed cases (Fig. S1B), as previously observed for Lassa fever28. We did observe an approximate 2:1 male-to-female ratio among confirmed cases, in contrast to previous conclusions that Lassa fever does not exhibit sex disparity11, though it would be difficult to determine whether this reflects a true difference, given the sampling bias inherent in clinical surveillance. Patients included healthcare workers, farmers, lawyers and students, demonstrating the broad reach of the 2018 surge.

Figure 1: Incidence of Lassa virus in Nigeria in recent years.

Figure 1: Incidence of Lassa virus in Nigeria in recent years.

a) Number of clinically suspected Lassa fever cases (blue) and RT-qPCR-positive cases (orange) tested at ISTH monthly from January 2012 to February 2018. Counts are those reported by ISTH. Gray shading denotes dry season months in Nigeria, when Lassa cases are typically highest. b) Samples processed at ISTH from January 1 to March 13, 2018. Outcome data, where available, are up to date as of March 22.

Lassa virus sequencing of patient samples from 2018 surge

To investigate the viral population underpinning this surge, we performed unbiased sequencing and assembled Lassa virus genomes on a subset of RT-qPCR-positive patient samples (Fig. 1B). We obtained complete or high-quality partial Lassa virus genomes from 14 out of 26 RTqPCR- positive patient samples. Table S1 summarizes sequence and assembly quality metrics for these samples. The mean unambiguous assembly length of these genomes was 9,039 bases (4,450-10,610) and mean coverage depth was 193x (1-1,834). 12 samples did not readily produce high-quality Lassa virus genomes. We did not find evidence consistent with other pathogenic viral infections in any of the samples from 2018, with the depth of sequencing available.

The 14 patients from whom we assembled Lassa virus genomes were reflective of the demographic characteristics of the larger cohort, including age (Fig. S1A), sex (Table 1) and geographic distribution (Fig. S1B). Clinically, the picture is of a nonspecific febrile illness that sometimes develops into a bleeding diathesis. Hemorrhage was documented in 2 of the 3 patients who died and in at least 3 of the 9 who recovered, suggesting a range of disease severity29. This is broadly consistent with clinical descriptions of Lassa fever: patients typically present with nonspecific symptoms, including fever, headache, malaise and general weakness, often indistinguishable from malaria or common viral diseases. Case fatality rates, though challenging to determine, are estimated at 15-20% among hospitalized cases11, though a recent study estimated case fatality rates in Nigeria during 2015-2016 to be 60%30.

Table 1. Demographic data and symptoms as reported for 14 patients whose virus was sequenced at ACEGID in 2018.

ID Age/Sex State Symptom onset Sample Collection Symptoms Outcome Genbank #
0026 32y M Edo 2017-12-29 2018-01-07 Fever, headache, weakness Recovered MH157043, MH157046
0097 44y M Ondo 2018-01-08 2018-01-15 Fever, abdominal pain, sore throat, weakness Recovered MH157049, MH157035
0541 18y F Edo 2018-01-30 2018-02-01 Fever, headache, abdominal pain Recovered MH157048, MH157044
0611 41y F Ebonyi 2018-02-02 Fever, headache, unspecified bleeding MH157039
0664 20y F Ondo 2018-02-04 Fever, abdominal pain MH157053, MH157028
0959 32y M Edo 2018-02-03 2018-02-12 Fever, vomiting, diarrhea, haematuria, weakness Died MH157042, MH157032
0998 32y M Edo 2018-02-05 2018-02-13 Fever, abdominal pain, sore throat, cough, weakness Recovered MH157030
1024 25y M Edo 2018-02-01 2018-02-14 Fever, headache, cough, general body pain, weakness Recovered MH157047, MH157037
1079 43y M Ondo 2018-02-07 2018-02-15 Fever, headache, abdominal pain, vomiting, diarrhea, bleeding, sore throat, weakness Recovered MH157029, MH157038
1177 33y M Edo 2018-02-04 2018-02-18 Fever, weakness, abdominal pain, sore throat, haematemesis Died MH157036, MH157034
1375 48y M Ondo 2018-02-16 2018-02-23 Fever, abdominal pain, headache, sore throat, vomiting, diarrhea, weakness Died MH157033, MH157045
1381 30y F Kogi 2018-02-08 2018-02-23 Fever, abdominal pain, headache, sore throat, diarrhea, haematemesis Recovered MH157040, MH157041
1392 14y F Edo 2018-02-16 2018-02-24 Fever, vomiting, cough, haematuria Recovered MH157051, MH157052
1643 27y M Edo 2018-02-25 2018-03-05 Fever, headache, sore throat Recovered MH157031, MH157050

To look for evidence of a novel viral genetic variant or sustained human-to-human transmission driving the 2018 case surge, we performed phylogenetic analysis of these 14 genomes from 2018. A maximum likelihood phylogeny shows that the 2018 genomes fall within previously known Lassa virus diversity in Nigeria (Fig. 2A) and do not display substantial clustering by date of sampling, consistent with multiple zoonotic transmissions. Estimated dates for the branch points of closely related 2018 samples in this small dataset, which are in the range of years, do not support a surge in human-to-human transmission in 2018 (Fig. S2). We also identified several intra-host Single Nucleotide Variants at a minor allele frequency >5% in 5 of the 14 patient samples, indicating some virus evolution and de novo mutation within hosts. However, none of these variants were in coding regions and only 1 was shared between samples (Table S2).

Figure 2. Distribution of Lassa virus genetic diversity in Nigeria.

Figure 2. Distribution of Lassa virus genetic diversity in Nigeria.

a) Maximum likelihood phylogenetic tree of the S segment of the Lassa virus genome. The tree incorporates the 77 new sequences presented here alongside 193 previously published sequences from Nigeria and the Mano River Union (in gray). The 77 new samples are coloured by geographic region in which the patient resides. Samples from 2018 are in bold. b) Map of Nigeria highlighting the states from which the 77 new sequences originate and the number of samples from each state. Colours are the same as in A. Kogi state, at the intersection of the 2 rivers, is shown in striped purple reflecting the clustering of the single sequenced sample from this state with others from the southwest region in A. The location of Irrua Specialist Teaching Hospital is marked in yellow.

Genomic epidemiology of Lassa virus in Nigeria

We next assessed these genomes in the context of the recent history of Lassa virus diversity in Nigeria, to determine whether the larger picture showed patterns that could help explain the recent surge. To do so, we extended our dataset to include 63 new Lassa virus genomes from RT-qPCR-positive patient samples collected at ISTH between August 2015 and November 2016 (BioProject accession PRJNA436552; Table S3). The patients resided in 11 states, with most (68%) coming from Edo and Ondo. This combined dataset considerably expands and updates previous phylogenetic trees of Lassa virus in Nigeria.

Samples from 2015-2018 cluster geographically on the phylogenetic tree. All eleven samples sequenced here from northern Nigeria fall into lineage III (Fig. 2B), increasing our sampling of this lineage more than threefold. These samples confirm the high genetic diversity of this lineage and make clear that it is a regionally defined variant of Lassa virus. Our dataset further identifies a separation in lineage II between samples from southwestern and eastern states, with samples from the eastern states of Ebonyi, Taraba and Anambra forming a distinct sublineage (Fig. 2B). This pattern of distinct regional lineages, each internally diverse, indicates that Lassa virus has remained stably separated in the rodent populations of these regions; for example, the most recent common ancestor of lineage II occurred around 235 years ago (95% CI: 187-283; Fig. S2).

The observed clustering aligns with the courses of the Niger and Benue rivers in Nigeria (Fig. 2B), suggesting that these major rivers present natural barriers to Mastomys rodents. This pattern further supports a key role for the rodent reservoir, and not humans, in the ongoing transmission of Lassa virus. Together with the long branch lengths of these groups – suggestive of extensive, uncaptured Lassa virus diversity in these regions – these results indicate sequestering of the rodent population and their associated Lassa virus lineages in these regions.

DISCUSSION

We undertook genome sequencing of Lassa virus from patient samples to assess whether intrinsic properties of the viral genomes contributed to the recent increase in Lassa fever cases in Nigeria. In our initial dataset of 14 genomes from 2018, we observe no evidence that either a particular viral variant or extensive human-to-human transmission drove the surge. Lassa virus genomes both from 2018 and from 2015-16 were broadly distributed across different Lassa virus lineages, suggesting that no single variant was associated with the recent increase in Lassa fever. Furthermore, we do not observe phylogenetic clustering of Lassa virus genomes from samples collected close in time, as would be expected if this surge were driven by humanto- human transmission. The absence of these patterns supports the assertion that Lassa virus transmission in 2018 was sustained by multiple distinct cross-species transmission events, consistent with previous observations12,13. These findings suggest future studies of the 2018 increase in cases prioritize investigating changes in the rodent reservoir population as well as the role of heightened surveillance and clinical awareness31.

The data reported here also improve our understanding of Lassa virus genetic diversity across Nigeria, revealing clear geographic population structure and extensive diversity in regions that have previously been poorly sampled. Intriguingly, we see substantial genetic divergence between regions demarcated by two major rivers, suggesting the importance of established, local rodent populations in sustaining Lassa virus transmission13. Together, these results reaffirm the need for widespread geographic sampling of Lassa virus in Nigeria, including more extensive sampling from the rodent reservoir, in order to better understand its genetic diversity. A comprehensive knowledge of this diversity is critical for development of urgently needed Lassa fever diagnostics and vaccines2,3.

The 2018 Lassa fever cases in this study were sequenced locally in Nigeria, leveraging longterm investments to establish local, responsive genomics laboratory capacity. These data were then rapidly shared with key public health organisations, who recognized the value of genomic data to inform case tracking and management. Continued development of local genomics capacity and growth of these collaborations will facilitate a more agile and integrated approach to outbreaks. We envision a model for genomics-informed outbreak investigation in which locally generated sequence data is rapidly integrated with traditional epidemiological data to refine response strategies.

Supplementary Materials

Supplementary Materials

ACKNOWLEDGEMENTS

This project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Grant Numbers U19AI110818 and R01AI114855 to the Broad Institute (P.C.S.), Grant Numbers U19AI115589 and R44AI115754 to Tulane University (R.F.G.), and Grant Number U19AI135995 to The Scripps Research Institute (K.G.A.). Support was also received from the National Human Genome Research Institute, National Institutes of Health, Department of Health and Human Services, under Grant Numbers U01HG007480 and U54HG007480 to Redeemer’s University Nigeria (C.T.H.). This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This project has also been supported by World Bank project ACE019 to Redeemer’s University Nigeria (C.T.H.), the Henry M Jackson Foundation to Redeemer’s University Nigeria (C.T.H.) and the Broad Institute (P.C.S.), and the Bill and Melinda Gates Foundation to Harvard University (P.C.S.). K.J.S. is supported by a fellowship from the Human Frontier Science Program (LT000553/2016); K.G.B. is supported by a Shope Fellowship from the American Society of Tropical Medicine and Hygiene; K.G.A. is a Pew Biomedical Scholar supported by NIH NCATS CTSA UL1TR001114; P.C.S. is an Investigator supported by the Howard Hughes Medical Institute. All genomic data has been publicly released at NCBI under BioProject PRJNA436552. All 64 genomes reported from 2015-2016 are available in GenBank under accessions MH053463-MH053590 All 14 genomes reported from 2018 are available in GenBank under accessions MH157028- MH157053.

Footnotes

Publisher's Disclaimer: This is an Author Final Manuscript, which is the version after external peer review and before publication in the Journal. The publisher’s version of record, which includes all New England Journal of Medicine editing and enhancements, is available at 10.1056/NEJMoa1804498..

Contributor Information

Katherine J. Siddle, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Systems Biology, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, USA..

Philomena Eromon, African Center of Excellence for Genomics of Infectious Disease (ACEGID), Redeemer's University, Ede, Osun State, Nigeria..

Kayla G. Barnes, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Systems Biology, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, USA; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA..

Judith U. Oguzie, African Center of Excellence for Genomics of Infectious Disease (ACEGID), Redeemer's University, Ede, Osun State, Nigeria; Department of Biological Sciences, College of Natural Sciences, Redeemer’s University, Ede, Osun State, Nigeria..

Samar Mehta, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Beth Israel Deaconess Medical Center, Division of Infectious Diseases, Boston, Massachusetts, USA..

Ikponmwonsa Odia, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria..

Rickey Shah, Center for Systems Biology, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, USA.

Patrick Brehio, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

Sarah M. Winnicki, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

Christopher Iruolagbe, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

John Aiyepada, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Eghosa Uyigue, Department of Biological Sciences, College of Natural Sciences, Redeemer’s University, Ede, Osun State, Nigeria; Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Patience Akhilomen, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Grace Okonofua, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Bridget Chak, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Systems Biology, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, USA.

Dylan Kotliar, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Systems Biology, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, USA.

Blessing Osiemi, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Ekene Muoebonam, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Michael Airende, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Rachael Ukpetina, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Iguosadolo Nosamiefan, African Center of Excellence for Genomics of Infectious Disease (ACEGID), Redeemer's University, Ede, Osun State, Nigeria.

Paul Oluniyi, African Center of Excellence for Genomics of Infectious Disease (ACEGID), Redeemer's University, Ede, Osun State, Nigeria; Department of Biological Sciences, College of Natural Sciences, Redeemer’s University, Ede, Osun State, Nigeria.

Ephraim Ogbaini-Emovon, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Mahan Nekouin, Faculty of Arts and Sciences, Harvard University, Cambridge, Massachusetts, USA.

Onikepe A. Folarin, African Center of Excellence for Genomics of Infectious Disease (ACEGID), Redeemer's University, Ede, Osun State, Nigeria; Department of Biological Sciences, College of Natural Sciences, Redeemer’s University, Ede, Osun State, Nigeria.

Stephen F. Schaffner, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Systems Biology, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, USA; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.

Robert F. Garry, Tulane Health Sciences Center, Tulane University, New Orleans, LA 70118, USA.

Kristian G. Andersen, Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA; Scripps Translational Science Institute, La Jolla, California, USA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.

Daniel J. Park, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

Nathan L. Yozwiak, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Systems Biology, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, USA.

Bronwyn L. MacInnis, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.

George Akpede, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Sylvanus Okogbenin, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.

Peter Okokhere, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria; Department of Medicine, Irrua Specialist Teaching Hospital, Irrua, Nigeria; Department of Medicine, Faculty of Clinical Sciences, Ambrose Alli University, Ekpoma, Nigeria.

Pardis C. Sabeti, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Systems Biology, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, USA; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA; Howard Hughes Medical Institute, Chevy Chase, Maryland, USA..

Christian T. Happi, African Center of Excellence for Genomics of Infectious Disease (ACEGID), Redeemer's University, Ede, Osun State, Nigeria; Department of Biological Sciences, College of Natural Sciences, Redeemer’s University, Ede, Osun State, Nigeri; Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria..

References

  • 1.Geisbert TW. Predicting outcome and improving treatment for Lassa fever. Lancet Infect Dis 2018;18(6):594–5. [DOI] [PubMed] [Google Scholar]
  • 2.The Lancet Infectious Diseases. Lassa fever and global health security. Lancet Infect Dis 2018;18(4):357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.WHO. AN R&D BLUEPRINT FOR ACTION TO PREVENT EPIDEMICS. 2016. [Google Scholar]
  • 4.WHO. 2018 Annual review of diseases prioritized under the R&D Blueprint [Internet]. 2018. Available from: http://www.who.int/emergencies/diseases/2018prioritization-report.pdf [Google Scholar]
  • 5.McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986;314(1):20–6. [DOI] [PubMed] [Google Scholar]
  • 6.Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis 2010;51:1435–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Hadi CM, Goba A, Khan SH, et al. Ribavirin for Lassa fever postexposure prophylaxis. Emerg Infect Dis 2010;16(12):2009–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.NCDC. An update of Lassa fever outbreak in Nigeria March 25th 2018 [Internet]. 2018. Available from: http://www.ncdc.gov.ng/diseases/sitreps/?cat=5&name=An%20update%20of%20Lassa%2 0fever%20outbreak%20in%20Nigeria [Google Scholar]
  • 9.Monath TP, Newhouse VF, Kemp GE, Setzer HW, Cacciapuoti A. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 1974;185(4147):263–5. [DOI] [PubMed] [Google Scholar]
  • 10.Fisher-Hoch SP, Tomori O, Nasidi A, et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ 1995;311(7009):857–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hallam HJ, Hallam S, Rodriguez SE, et al. Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. NPJ Vaccines 2018;3:11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Andersen KG, Shapiro BJ, Matranga CB, et al. Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. Cell 2015;162:738–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Bowen MD, Rollin PE, Ksiazek TG, et al. Genetic diversity among Lassa virus strains. J Virol 2000;74(15):6992–7004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Manning JT, Forrester N, Paessler S. Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage. Front Microbiol 2015;6:1037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Whitmer SLM, Strecker T, Cadar D, et al. New Lineage of Lassa Virus, Togo, 2016. Emerg Infect Dis 2018;24(3):599–602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Matranga CB, Gladden-Young A, Qu J, et al. Unbiased Deep Sequencing of RNA Viruses from Clinical Samples. J Vis Exp [Internet] 2016;(113). Available from: http://dx.doi.org/10.3791/54117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Park D, Tomkins-Tinch C, Ye S, et al. broadinstitute/viral-ngs: v1.19.2 [Internet]. 2018. Available from: https://zenodo.org/record/1167849 [Google Scholar]
  • 18.Park DJ, Dudas G, Wohl S, et al. Ebola Virus Epidemiology, Transmission, and Evolution during Seven Months in Sierra Leone. Cell 2015;161(7):1516–26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Grabherr MG, Haas BJ, Yassour M, et al. Full-length transcriptome assembly from RNASeq data without a reference genome. Nat Biotechnol 2011;29(7):644–52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol 2014;15(3):R46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Siddle KJ, Metsky HC, Gladden-Young A, et al. Capturing diverse microbial sequence with comprehensive and scalable probe design [Internet]. bioRxiv. 2018 [cited 2018 Jun 5];279570. Available from: https://www.biorxiv.org/content/early/2018/03/12/279570 [Google Scholar]
  • 22.Yang X, Charlebois P, Macalalad A, Henn MR, Zody MC. V-Phaser 2: variant inference for viral populations. BMC Genomics 2013;14(1):674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 2013;30(4):772–80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hoang DT, Chernomor O, von Haeseler A, Minh BQ, Vinh LS. UFBoot2: Improving the Ultrafast Bootstrap Approximation. Mol Biol Evol 2018;35(2):518–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Nguyen L-T, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol 2015;32(1):268–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Drummond AJ, Suchard MA, Xie D, Rambaut A. Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol Biol Evol 2012;29(8):1969–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Shapiro B, Rambaut A, Drummond AJ. Choosing appropriate substitution models for the phylogenetic analysis of protein-coding sequences. Mol Biol Evol 2006;23(1):7–9. [DOI] [PubMed] [Google Scholar]
  • 28.Shaffer JG, Grant DS, Schieffelin JS, et al. Lassa fever in post-conflict Sierra Leone. PLoS Negl Trop Dis 2014;8(3):e2748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Okokhere P, Colubri A, Azubike C, et al. Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. Lancet Infect Dis [Internet] 2018;Available from: http://dx.doi.org/10.1016/S1473- 3099(18)30121-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Buba MI, Dalhat MM, Nguku PM, et al. Mortality Among Confirmed Lassa Fever Cases During the 2015-2016 Outbreak in Nigeria. Am J Public Health 2018;108(2):262–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Gire SK, Stremlau M, Andersen KG, et al. Emerging Disease or Diagnosis? Science 2012;338(6108):750–2. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Materials

RESOURCES